Wedbush Reiterates Neutral Rating, $5 PT on Sequenom on 4Q12 Revenues, EPS Loss

In a report published Friday, Wedbush reiterated its Neutral rating and $5.00 price target on Sequenom

. Wedbush noted, “SQNM posted 4Q12 sales of $34 MM and a loss of ($0.29), which topped our revenue estimate of $33 MM and missed our EPS loss estimate of ($0.22). Results topped Wall Street consensus revenue estimates of $32 MM and missed the EPS loss estimate of ($0.23). Importantly, it appears to us that 4Q12 MaterniT21 revenue exceeded the Street's expectations by about $1 MM.” Sequenom closed on Thursday at $4.49.